Hostname: page-component-848d4c4894-mwx4w Total loading time: 0 Render date: 2024-07-01T20:21:54.059Z Has data issue: false hasContentIssue false
  • English
  • Français

Neurobiologic basis of antidepressant safety profiles

Published online by Cambridge University Press:  16 April 2020

D Hackett  and
E Salinas
D Hackett
Affiliation:
Wyeth-Ayerst CRD, 80 Ave du President Wilson, 92031Paris la Defense cedex, France
E Salinas
Affiliation:
Wyeth-Ayerst CRD, 80 Ave du President Wilson, 92031Paris la Defense cedex, France
Get access

Summary

Venlafaxine is a serotonin-noradrenaline reuptake inhibitor (SNRI) that has no affinity for muscarinic, adrenergic or histaminergic receptors. In short-term trials, the adverse effects that occurred more often with venlafaxine than with placebo included nausea, somnolence, dizziness, dry mouth, and sweating. Rapid titration of the dose of venlafaxine to higher levels appeared, not unexpectedly, to be associated with an increased incidence of side effects. Side effects that appeared to be dose related included insomnia, nausea and sexual dysfunction. The incidence of nausea and dizziness was highest during the first 2 or 3 weeks of therapy and decreased rapidly thereafter. Somnolence also decreased over time. At high doses blood pressure increases were reported in a small percent of patients on venlafaxine and antidepressant drugs but were uncommon at the venlafaxine dose of 75–150 mg daily. Studies with venlafaxine in healthy volunteers indicate a low potential for drug-drug interactions. Overdoses have been reported in 14 of 3,082 patients administered venlafaxine in clinical trials, and no deaths were reported among these patients. Overdoses of venlafaxine induced mainly drowsiness and lethargy.

Keywords

venlafaxineserotonin-noradrenaline reuptake inhibitorsafetyneurobiologic actions
Type
Research Article
Information
European Psychiatry , Volume 12 , Issue S4 , 1997 , pp. 301s - 306s
Copyright
Copyright © Elsevier, Paris 1997

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Altamura, AC, Montgomery, SA, Wernicke, JFThe evidence for 20 mg a day of fluoxetine as the optimal dose in the treatment of depression. Br J Psychiatry 1988 153 (suppl 3) 109–112CrossRefGoogle Scholar
Beasley, CM Jr, Bosomworth, JC, Wernicke, JFFluoxetine: relationships among dose, response, adverse events, and plasma concentrations in the treatment of depression. Psychopharmacol Bull 1990; 26: 18–24Google ScholarPubMed
Bergeron, R, Blier, PCisapride for the treatment of nausea produced by selective serotonin reuptake inhibitors. Am J Psychiatry 1994; 151: 1084–1086Google ScholarPubMed
Bolden-Watson, C, Richelson, EBlockade by newly-developed antidepressants of biogenic amine uptake into rat brain synaptosomes. Life Sci 1993; 52: 1023–1029CrossRefGoogle ScholarPubMed
Clerc, GE, Ruimy, P, Verdeau-Paillès, JA double-blind comparison of venlafaxine and fluoxetine in patients hospitalized for major depression and melancholia. Int Clin Psychapharmacol 1994; 9: 139–143CrossRefGoogle ScholarPubMed
Cusack, B, Nelson, A, Richelson, EBinding of antidepressants to human brain receptors: focus on newer generation compounds. Psychopharmacology 1994; 114: 559–565CrossRefGoogle ScholarPubMed
Danjou, P, Hackett, DSafety and tolerance profile of venlafaxine. Int Clin Psychapharmacol 10suppl 21995 15–20CrossRefGoogle ScholarPubMed
Dierick, M, Ravizza, L, Realini, R, Martin, AA double-blind comparison of venlafaxine and fluoxetine for treatment of major depression in outpatients. Prog Neuropsychopharmacol Biol Psychiatry 1996; 20: 57–71CrossRefGoogle ScholarPubMed
Dornseif, BE, Dunlop, SR, Potvin, JH, Wernicke, JFEffect of dose escalation after low-dose fluoxetine therapy. Psychopharmacol Bull 1989; 25: 71–79Google ScholarPubMed
Dunbar, GC, Cohn, JB, Fabre, LFet al.A comparison of paroxetine, imipramine and placebo in depressed out-patients. Br J Psychiatry 1991; 159: 394–398CrossRefGoogle ScholarPubMed
Gründer, G, Wetzel, H, Schlößer, R, Benkert, OSubchronic antidepressant treatment with venlafaxine or imipramine and effects on blood pressure and heart rate: assessment by automatic 24 hour monitoring. Pharmacopsychiatry 1996; 29: 72–78CrossRefGoogle ScholarPubMed
Khan, A, Rudolph, R, Baumel, B, Ferguson, JVenlafaxine in depressed geriatric outpatients: an open-label clinical study. Psychopharmacol Bull 1995; 31: 537–545Google ScholarPubMed
Otton, SV, Ball, SE, Inaba, T, Sellers, EMInteraction of venlafaxine, a new antidepressant, with CYP2D6 in human liver microsomes (abstract). Neuropsychopharmacology 1994 10 (suppl) 219Google Scholar
Pande, AC, Sayler, MEAdverse events and treatment discontinuations in fluoxetine clinical trials. Int Clin Psychopharmacol 1993; 8: 267–269CrossRefGoogle ScholarPubMed
Parker, V, Paerg, L, Maloney, Ket al.Effect of age and sex on the pharmacokinetics of venlafaxine (abstract). J Clin Pharmacol 1990 30 832Google Scholar
Preskorn, SH, Janicak, PG, Davis, JM, Ayd, FJ. Advances in the pharmacotherapy of depressive disorders. In: Janicak, PG, Davis, JM, Preskorn, SH, Ayd, FJ, eds. Principles and Practice of Psychopharmacotherapy Vol 1. Williams and Wilkins;2:1–24Google Scholar
Rudolph, R, Entsuah, R, Derivan, AEarly clinical response in depression to venlafaxine hydrochloride (abstract). Biol Psychiatry 1991; 29: 630SGoogle Scholar
Schweizer, E, Feighner, J, Mandos, LA, Rickels, KComparison of venlafaxine and imipramine in the acute treatment of major depression in outpatients. J Clin Psychiatry 1994; 55: 104–108Google ScholarPubMed
Shrivastava, RK, Cohn, C, Crowder, Jet al.Long-term safety and clinical acceptability of venlafaxine and imipramine in outpatients with major depression. J Clin Psychopharmacol 1994; 14: 322–329CrossRefGoogle ScholarPubMed
Submit a response

Comments

No Comments have been published for this article.